Literature DB >> 15289847

Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer.

Trinidad Caldés1, Javier Godino, Ana Sanchez, Cesar Corbacho, Miguel De la Hoya, Jose Lopez Asenjo, Carmen Saez, Julian Sanz, Manuel Benito, Santiago Ramon Y Cajal, Eduardo Diaz-Rubio.   

Abstract

Hereditary non-polyposis colorectal cancer (HNPCC) represents 1-3% of all colorectal cancers. HNPCC is caused by a constitutional defect in a mismatch repair (MMR) gene, most commonly affecting the genes MLH1, MSH2 and MSH6. The MMR defect results in an increased cancer risk, with the greatest lifetime risk for colorectal cancer and other cancers associated to HNPCC. The HNPCC-associated tumor phenotype is generally characterized by microsatellite instability (MSI) and immunohistochemical loss of expression of the affected MMR protein. The aim of this study was to determine the sensitivity of IHC for MLH1, MSH2 and MSH6, and MSI analysis in tumors from known MMR gene mutation carriers. Fifty-eight paired normal and tumor samples from HNPCC families enrolled in our high-risk colorectal cancer registry were studied for the presence of germline mutations in MLH1, MSH2 and MSH6 by DGGE and direct sequencing. MSI analysis and immunostaining for MLH1, MSH2 and MSH6 were evaluated. Of the 28 patients with a real pathogenic mutation, loss of immunohistochemical expression for at least 1 of these MMR proteins was found, and all except 1 have MSI-H. Sensitivity by MSI analysis was 96%. IHC analysis had a sensitivity of 100% in detecting MMR deficiency in carriers of a pathogenic MMR mutation, and can be used to predict which gene is expected to harbor the mutation for MLH1, MSH2 and MSH6. This study suggests that both analyses are useful for selecting high-risk patients because most MLH1, MSH2 and MSH6 gene carriers will be detected by this 2-step approach. This practical method should have immediate application in the clinical work of patients with inherited colorectal cancer syndromes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15289847

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  13 in total

1.  Reassessing the TARBP2 mutation rate in hereditary nonpolyposis colorectal cancer.

Authors:  Pilar Garre; Pedro Pérez-Segura; Eduardo Díaz-Rubio; Trinidad Caldés; Miguel de la Hoya
Journal:  Nat Genet       Date:  2010-10       Impact factor: 38.330

2.  The germline MLH1 K618A variant and susceptibility to Lynch syndrome-associated tumors.

Authors:  Fabiola Medeiros; Noralane M Lindor; Fergus J Couch; W Edward Highsmith
Journal:  J Mol Diagn       Date:  2012-03-13       Impact factor: 5.568

3.  Microsatellite instability screening in colorectal adenomas to detect Lynch syndrome patients? A systematic review and meta-analysis.

Authors:  Parag D Dabir; Carlijn E Bruggeling; Rachel S van der Post; Bas E Dutilh; Nicoline Hoogerbrugge; Marjolijn J L Ligtenberg; Annemarie Boleij; Iris D Nagtegaal
Journal:  Eur J Hum Genet       Date:  2019-11-06       Impact factor: 4.246

4.  Clinical phenotype and prevalence of hereditary nonpolyposis colorectal cancer syndrome in Chinese population.

Authors:  Yuan-Zhi Zhang; Jian-Qiu Sheng; Shi-Rong Li; Hong Zhang
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

5.  Testing women with endometrial cancer to detect Lynch syndrome.

Authors:  Janice S Kwon; Jenna L Scott; C Blake Gilks; Molly S Daniels; Charlotte C Sun; Karen H Lu
Journal:  J Clin Oncol       Date:  2011-05-02       Impact factor: 44.544

6.  Prediction of germline mutations and cancer risk in the Lynch syndrome.

Authors:  Sining Chen; Wenyi Wang; Shing Lee; Khedoudja Nafa; Johanna Lee; Kathy Romans; Patrice Watson; Stephen B Gruber; David Euhus; Kenneth W Kinzler; Jeremy Jass; Steven Gallinger; Noralane M Lindor; Graham Casey; Nathan Ellis; Francis M Giardiello; Kenneth Offit; Giovanni Parmigiani
Journal:  JAMA       Date:  2006-09-27       Impact factor: 56.272

7.  Two novel germline mutations of MLH1 and investigation of their pathobiology in hereditary non-polyposis colorectal cancer families in China.

Authors:  Chao-Fu Wang; Xiao-Yan Zhou; Tai-Ming Zhang; Ye Xu; San-Jun Cai; Da-Ren Shi
Journal:  World J Gastroenterol       Date:  2007-12-14       Impact factor: 5.742

8.  Classifying MLH1 and MSH2 variants using bioinformatic prediction, splicing assays, segregation, and tumor characteristics.

Authors:  Sven Arnold; Daniel D Buchanan; Melissa Barker; Lesley Jaskowski; Michael D Walsh; Genevieve Birney; Michael O Woods; John L Hopper; Mark A Jenkins; Melissa A Brown; Sean V Tavtigian; David E Goldgar; Joanne P Young; Amanda B Spurdle
Journal:  Hum Mutat       Date:  2009-05       Impact factor: 4.878

9.  Cancer risk and overall survival in mismatch repair proficient hereditary non-polyposis colorectal cancer, Lynch syndrome and sporadic colorectal cancer.

Authors:  Pilar Garre; Lorena Martín; Inmaculada Bando; Alicia Tosar; Patricia Llovet; Julián Sanz; Atocha Romero; Miguel de la Hoya; Eduardo Díaz-Rubio; Trinidad Caldés
Journal:  Fam Cancer       Date:  2014-03       Impact factor: 2.375

10.  Frequency and variability of genomic rearrangements on MSH2 in Spanish Lynch Syndrome families.

Authors:  Atocha Romero; Pilar Garre; Olivia Valentin; Julian Sanz; Pedro Pérez-Segura; Patricia Llovet; Eduardo Díaz-Rubio; Miguel de la Hoya; Trinidad Caldés
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.